Amicus Therapeutics, Inc.

NASDAQ•FOLD

CEO: Mr. Bradley L. Campbell M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2007-05-31

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Contact Information

47 Hulfish Street, Princeton, NJ, 08542, United States

609-662-2000

amicusrx.com

Market Cap

$4.51B

P/E (TTM)

-163.8

17.6

Dividend Yield

52W High

$14.39

52W Low

$5.51

52W Range

100%

Rank59Top 87.6%

2.2

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$185.21M+0.00%

4-Quarter Trend

EPS

$0.01+0.00%

4-Quarter Trend

FCF

$15.95M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Product Sales Growth Strong Net product sales reached $634.2M USD, showing a $105.9M increase driven by Galafold and Pombiliti growth.

Net Loss Significantly Reduced Net loss narrowed by $29.0M USD to $(27.1M) in 2025, reflecting improved operational results compared to prior year.

BioMarin Merger Agreement Signed Definitive merger agreement signed December 19, 2025, offering $14.50 cash per share, expected close Q2 2026.

Pipeline Investment Dimerix License R&D costs rose $26.5M USD, primarily due to $30.0M upfront payment for U.S. commercialization rights of DMX-200.

Risk Factors

BioMarin Transaction Completion Risk Failure to complete pending BioMarin merger could adversely affect business, financial results, and operations; subject to closing conditions.

Heavy Product Sales Dependence Business heavily depends on Galafold and Pombiliti sales; delays or market erosion could materially harm financial condition.

Intellectual Property Litigation Exposure Ongoing patent litigation, including Hatch-Waxman challenges, requires significant resources and uncertain outcomes affecting exclusivity.

Anticipated Continued Operating Losses Company incurred significant losses and anticipates continuing losses, requiring substantial capital to fund operations and development.

Outlook

Finalize BioMarin Acquisition Closing Transaction expected to close in second quarter 2026, subject to regulatory clearances and stockholder approval conditions.

Advance Pipeline and Commercialization Continue developing next-generation therapies and preparing for potential U.S. commercial launch of DMX-200 if regulatory approvals are secured.

Maintain Cash Position Runway Current cash position sufficient for next 12 months operations, excluding Merger impact; future capital needs depend on pipeline expansion.

Peer Comparison

Revenue (TTM)

LEGN

$1.03B

+64.2%

KNSA

$677.56M

+60.1%

FOLD

$634.21M

+20.0%

Gross Margin (Latest Quarter)

BEAM

95.0%

-471.3pp

TARS

92.8%

-14.0pp

ARQT

91.0%

+3.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
IBRX	$8.80B	-24.1	64.3%	175.0%
BLTE	$6.35B	-69.7	-42.7%	0.0%
CDTX	$5.61B	-18.6	-60.1%	0.4%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

13.9%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

75%

Volatile Cash Flow

Deep Research

Next earnings:Apr 29, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data